Publications by authors named "Emily Wen"

Messenger RNA (mRNA) vaccines represent a landmark in vaccinology, especially with their success in COVID-19 vaccines, which have shown great promise for future vaccine development and disease prevention. As a platform technology, synthetic mRNA can be produced with high fidelity using in vitro transcription (IVT). Magnesium plays a vital role in the IVT process, facilitating the phosphodiester bond formation between adjacent nucleotides and ensuring accurate transcription to produce high-quality mRNA.

View Article and Find Full Text PDF

Background: General consumers can now easily access drug information and quickly check for potential drug-drug interactions (PDDIs) through mobile health (mHealth) apps. With aging population in Canada, more people have chronic diseases and comorbidities leading to increasing numbers of medications. The use of mHealth apps for checking PDDIs can be helpful in ensuring patient safety and empowerment.

View Article and Find Full Text PDF
Article Synopsis
  • Pseudomonas aeruginosa is a harmful bacterium that infects various body parts, particularly in people with cystic fibrosis (CF), as it takes advantage of the compromised epithelial cells.
  • This study investigates how P. aeruginosa induces the formation of blebs (bulges) in infected cells, revealing that this process is independent of actin and can be influenced by osmotic conditions, particularly involving the cystic fibrosis transmembrane-conductance regulator (CFTR).
  • Findings reveal that CFTR-deficient cells have increased formation of these blebs, helping P. aeruginosa replicate and persist in the host, highlighting a potential pathway for bacterial survival during infection.
View Article and Find Full Text PDF

Conventional influenza vaccines can prevent infection, but their efficacy depends on the degree of antigenic "match" between the strains used for vaccine preparation and those circulating in the population. A universal influenza vaccine based on invariant regions of the virus, able to provide broadly cross-reactive protection, without requiring continuous manufacturing update, would solve a major medical need. Since the temporal and geographical dominance of the influenza virus type and/or subtype (A/H3, A/H1, or B) cannot yet be predicted, a universal vaccine, like the vaccines currently in use, should include both type A and type B influenza virus components.

View Article and Find Full Text PDF